Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IM-1021 · 1 trial · 2 indications
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0, including serious adverse events (SAEs), AEs of interest (AEI), AEs leading to discontinuation, and deaths
Type, frequency, seriousness, and severity of AEs graded using the NCI-CTCAE v6.0, including SAEs, AEIs, AEs leading to discontinuation, and deaths
| Arm | Type | Description |
|---|---|---|
| Part A: IM-1021 Dose Escalation | EXPERIMENTAL | IM-1021 given into the vein (IV; intravenously) |
| Part B: IM-1021 Monotherapy Dose Expansion | EXPERIMENTAL | IM-1021 given into the vein (IV; intravenously) |
| Name | Type | Description |
|---|---|---|
| IM-1021 | DRUG | IM-1021 is an antibody-drug conjugate |
Inclusion Criteria: 1. Informed consent signed by the participant prior to conducting study-specific procedures 2. ≥18 years of age 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 4. Histological or cytological diagnosis of: Part A: advanced B-cell lymphomas or sol...
IM-1021 is an investigational small molecule antibody-drug conjugate being developed by Immunome, Inc. for the treatment of solid malignancies and hematologic malignancies. It is currently in Phase 1 clinical development and is designed to target the ROR1 protein. IM-1021 has not been approved by the FDA.
IM-1021 targets ROR1, a receptor tyrosine kinase expressed on tumor cells. It is an antibody-drug conjugate, meaning it uses an antibody to deliver a cytotoxic payload to cells expressing ROR1. This targeted approach aims to concentrate anti-tumor activity on malignant cells while limiting effects on normal tissue.
IM-1021 is being developed by Immunome, Inc., a biopharmaceutical company that trades on the Nasdaq under the ticker symbol IMNM. Immunome is the sponsor of the ongoing Phase 1 clinical trial evaluating IM-1021 in patients with advanced cancer.
IM-1021 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The single ongoing study is a Phase 1 trial that is currently recruiting participants with advanced solid malignancies and hematologic malignancies.
IM-1021 is being evaluated in one active clinical trial, NCT06823167, titled A Phase 1 Study of IM-1021 in Participants With Advanced Cancer. The trial is recruiting and plans to enroll 190 participants across the United States, Denmark, France, and Spain. It enrolls adults 18 years and older.
Yes, IM-1021 is also referred to as 1021. Both names refer to the same investigational small molecule antibody-drug conjugate developed by Immunome, Inc. that targets ROR1 and is being studied in a Phase 1 trial in patients with advanced cancer.